methods communications\(\def\hfill{\hskip 5em}\def\hfil{\hskip 3em}\def\eqno#1{\hfil {#1}}\)

Journal logoSTRUCTURAL BIOLOGY
COMMUNICATIONS
ISSN: 2053-230X

Optimized bacterial expression of a synthetic BRIL antibody

crossmark logo

aSir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom
*Correspondence e-mail: [email protected], [email protected]

Edited by A. Buschiazzo, Institut Pasteur de Montevideo, Uruguay (Received 21 December 2025; accepted 13 February 2026; online 17 March 2026)

The use of monoclonal fragments antigen binding (Fabs) is a prevalent methodology facilitating protein structure determination via both crystallography and cryo-EM. The development of a synthetic Fab against the BRIL domain improved the accessibility of this approach, providing a general fiducial applicable to any protein of interest via the simple curation of a BRIL fusion protein. Here, we document the generation of a T7 Express ΔcybC strain allowing contaminant-free bacterial expression of the synthetic anti-BRIL Fab BAG2. We also report the crystal structure of BAG2 in complex with native cytochrome b562, a complex arising from expression in canonical Escherichia coli strains.

1. Introduction

Single-particle analysis cryo-electron microscopy (SPA cryoEM) has become the primary workhorse for high-resolution protein structure elucidation in recent years owing to its low sample requirements and its wider accommodation of heterogeneous samples and/or complexes (De Zorzi et al., 2016View full citation; Chua et al., 2022View full citation). Nevertheless, macromolecule size remains a fundamental limitation within SPA cryoEM, with substantially fewer high-resolution reconstructions performed for macromolecules below 100 kDa; thus, certain protein classes remain underrepresented.

SPA cryoEM presents an attractive proposition for the structural study of integral membrane proteins, which typically exhibit more incompatibilities with X-ray crystallography or NMR. Nonetheless, integral membrane proteins are typically smaller than 100 kDa; thus, several techniques to append membrane proteins, increasing their applicability for cryoEM, have been developed.

Monoclonal fragments antigen binding (Fabs) present one such methodology to assist the structural elucidation of small membrane proteins. Initially Fabs were utilized to assist membrane-protein crystallization, whereby their large polar surface area facilitates crystal contact formation (Kermani, 2021View full citation). Subsequently Fabs were deployed as fiducials in cryoEM, artificially increasing the particle mass by ∼50 kDa and facilitating image alignment, enabling the high-resolution elucidation of several membrane proteins below the 100 kDa threshold (Wu et al., 2012View full citation; Walsh et al., 2018View full citation; Kim et al., 2019View full citation; Shionoya et al., 2024View full citation; Pan et al., 2020View full citation).

The generation of Fabs against each protein of interest presents a substantial bottleneck in their application to nascent projects. Nevertheless, a recently developed panel of synthetic Fabs raised against the BRIL domain offer universal fiducials which may be applied to any target via assembly of a protein–BRIL fusion (Mukherjee et al., 2020View full citation; Tsutsumi et al., 2020View full citation; Sverak et al., 2024View full citation; Luo et al., 2025View full citation; Zhang et al., 2025View full citation).

We sought to apply this methodology to a small membrane protein of interest within our laboratory; however, we observed the anti-BRIL Fab (BAG2) to co-purify with the soluble cytochrome b562 when grown in typical Escherichia coli expression strains. Here, we report the generation of a T7 Express ΔcybC strain, offering an alternative bacterial system for the expression of BAG2 which completely prevents the co-purification of cytochrome b562.

2. Materials and methods

2.1. Overexpression and purification of BAG2

E. coli expression strains [BL21-Gold, Rosetta (DE3), C43 (DE3) Pro+, T7 Express and T7 Express ΔcybC] were transformed with a pRH2.2 expression vector harbouring the synthetic, anti-BRIL Fab BAG2 (Mukherjee et al., 2020View full citation). Cultures were grown at 37°C in 2×YT medium supplemented with 100 µg ml−1 carbenicillin and 1 mM MgSO4 until the OD600 reached 0.6. Protein expression was induced by the addition of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and continued for 4 h at 37°C.

Cells were harvested via centrifugation at 6000g for 15 min. The cell pellets were resuspended in an appropriate volume of 50 mM Tris, 500 mM NaCl pH 8 supplemented with cOmplete EDTA-free protease-inhibitor cocktail tablets (Roche). The cells were lysed via four passes through an Emulsiflex-C3 cell disruptor (Avestin). The cell lysate was incubated at 58°C for 30 min to denature bacterial proteins before cell debris was removed via centrifugation at 50 000g for 1 h at 4°C. The resulting supernatant was filtered through a 0.22 µm syringe filter and bound to a HiTrap Protein L column (Cytiva) pre-equilibrated in 50 mM Tris, 500 mM NaCl pH 8. The column was washed with 10 column volumes (CV) of 50 mM Tris, 500 mM NaCl pH 8 and the protein was eluted with 0.1 M acetic acid. Fractions containing BAG2 were pooled and loaded onto a 1 ml RESOURCE S column (Cytiva) pre-equilibrated in 50 mM sodium acetate pH 5.0. The column was washed with 5 CV of 50 mM sodium acetate pH 5.0 and the protein was eluted using a linear gradient to 100% 50 mM sodium acetate, 2 M NaCl pH 5.0 over 25 CV. Fractions containing BAG2 were dialysed overnight at 4°C against 20 mM Tris, 150 mM NaCl pH 8, concentrated in a 10 kDa molecular-weight cutoff (MWCO) concentrator (Sartorius) and snap-frozen for later use.

2.2. BAG2–BRIL fusion-protein complex formation

BAG2 was combined with BRIL fusion protein at a 1.2× molar excess, incubated on ice for 60 min and injected onto a Superose 6 10/300 Increase column (Cytiva). Successful complex formation was established via the analysis of elution fractions by SDS–PAGE.

2.3. Crystallization and structure determination of the cytochrome b562–BAG2 complex

Fractions corresponding to the cytochrome b562–BAG2 complex were pooled and concentrated to 5–10 mg ml−1 in a 50 kDa MWCO concentrator (Sartorius). Crystallization screens were prepared by mixing 100 nl cytochrome b562–BAG2 complex and 100 nl precipitant solution. The complex crystallized in space group P65 (a = 88.72, b = 88.72, c = 162.51 Å, α = 90, β = 90, γ = 120°) in a precipitant solution from the Morpheus screen (Gorrec, 2009View full citation) comprising 0.1 M MOPS/HEPES–Na pH 7.5, 0.03 M bromide, 0.03 M fluoride, 0.03 M imidazole, 12.5%(w/v) PEG 1000, 12.5%(w/v) PEG 3350, 12.5%(v/v) MPD. Diffraction data were collected on beamline I04 at Diamond Light Source (DLS). Data reduction and processing was performed using the xia2–DIALS pipeline (Winter et al., 2018View full citation; Winter, 2010View full citation).

The crystal structure of the native cytochrome b562–BAG2 complex was solved by molecular replacement with a modified version of the BAG2–BRIL domain structure (PDB entry 6cbv) in which the BRIL domain was replaced with cytochrome b562, using Phaser (McCoy et al., 2007View full citation). The resulting model was refined using Phenix (Liebschner et al., 2019View full citation) interspersed with manual inspection and adjustment in Coot (Emsley & Cowtan, 2004View full citation). Crystallization, diffraction data-collection and processing and refinement statistics are given in Tables 1[link], 2[link] and 3[link], respectively.

Table 1
Crystallization of the native cytochrome b562–BAG2 complex

Method Sitting-drop vapour diffusion
Plate type MRC 2-lens
Temperature (K) 277
Protein concentration (mg ml−1) 10
Buffer composition of protein solution 20 mM Tris, 150 mM NaCl, 0.02% DDM pH 8
Composition of reservoir solution 0.1 M MOPS/HEPES–Na pH 7.5, 0.03 M bromide, 0.03 M fluoride, 0.03 M imidazole, 12.5%(w/v) PEG 1000, 12.5%(w/v) PEG 3350, 12.5%(v/v) MPD
Volume and ratio of drop 100 nl protein plus 100 nl reservoir (1:1)
Volume of reservoir (µl) 40
Composition of cryoprotectant Reservoir solution

Table 2
Data collection and processing of the native cytochrome b562–BAG2 complex

Values in parentheses are for the highest resolution shell.

PDB code 9tmp
Beamline I04, DLS
Wavelength (Å) 0.9537
Temperature (K) 100
Detector EIGER2 XE 16M
Total rotation range (°) 360
Rotation per image (°) 0.1
Exposure time per image (s) 0.0071
Space group P65
a, b, c (Å) 88.72, 88.72, 162.51
α, β, γ (°) 90, 90, 120
Mosaicity (°) 0.087
Resolution range (Å) 76.84–2.64 (2.68–2.64)
Total No. of reflections 441423 (14769)
No. of unique reflections 21369 (1061)
Completeness (%) 100 (100)
Multiplicity 20.66 (13.92)
I/σ(I)〉 11.18 (0.17)
CC1/2 0.999 (0.119)
Rp.i.m. 0.036 (1.922)
Overall B factor from Wilson plot (Å2) 74.47

Table 3
Structure refinement of the native cytochrome b562–BAG2 complex

Values in parentheses are for the highest resolution shell.

Resolution range (Å) 44.28–2.65 (2.79–2.65)
Completeness (%) 91.64 (42.28)
No. of reflections, working set 19287 (1277)
No. of reflections, test set 1008 (56)
Final Rcryst 0.2077 (0.4017)
Final Rfree 0.2414 (0.4344)
No. of non-H atoms
 Macromolecules 4106
 Ligands 43
 Solvent 1
 Total 4150
R.m.s. deviations
 Bond lengths (Å) 0.008
 Angles (°) 0.9
Average B factors (Å2)  
 Macromolecules 109.78
 Ligands 128.52
 Solvent 66.98
Ramachandran plot
 Favoured regions (%) 97.57
 Allowed (%) 2.43
 Outliers (%) 0

2.4. Knockout generation

The T7 Express ΔcybC strain was derived from T7 Express (NEB) using lambda Red recombination, as described previously (Datsenko & Wanner, 2000View full citation). Briefly, the aph cassette was amplified from donor plasmid pKD4 using primers oBFC307 and oBFC308 (Table 4[link]) and the linear product introduced to the parental T7 Express strain carrying the Red helper plasmid pKD46. Transformants were initially selected by growth on LB agar supplemented with 50 µg ml−1 kanamycin and the ΔcybC::aph allele verified by colony PCR using flanking primers oBFC309 and oBFC310 (Table 4[link]). Finally, the ΔcybC::aph allele was P1 transduced into a fresh T7 Express background as described previously (Thomason et al., 2007View full citation).

Table 4
Primers utilized in this study

Primer name Primer sequence (5′–3′)
oBFC307 GTGAAGGATGAAGTGTAAATAAAAAAGGAAGTGAGCAATGCATATGAATATCCTCCTTAG
oBFC308 GCAACAGGGAAATGAGGAATTAACGATACTTCTGGTGATAGTGTAGGCTGGAGCTGCTTC
oBFC309 CCCGTTAGTGAAATCACCATCGCAG
oBFC310 AGGGTATTTCCCTCTCCGGCG

3. Results

3.1. BAG2 co-purifies with cytochrome b562

Initially, BAG2 expression was performed according to Mukherjee et al. (2015View full citation, 2020View full citation) utilizing the E. coli BL21-Gold strain. Subsequent Protein-L and cation-exchange steps yielded a homogenous sample comprising the ∼25 kDa heavy (HC) and light chains (LC) of BAG2 and an unexpected species of ∼15 kDa, as indicated by SDS–PAGE (Figs. 1[link]a and 1[link]c). Expression of BAG2 in alternative E. coli expression strains [Rosetta (DE3), C43 (DE3) Pro+ and T7 Express] yielded identical results.

[Figure 1]
Figure 1
BAG2 co-purifies with a 15 kDa protein which competes for BRIL binding. (a) SDS–PAGE of Protein L elution fractions following BAG2 overexpression in BL21-Gold indicating co-purification of a 15 kDa protein, later confirmed as cytochrome b562. (b) Cation-exchange trace of pooled Protein L elution fractions following BAG2 overexpression in BL21-Gold. (c) SDS–PAGE of cation-exchange fractions following BAG2 overexpression in BL21-Gold, indicating that BAG2 maintains a stable complex with the 15 kDa protein later identified as cytochrome b562 throughout purification. (d) Region of interest from a size-exclusion chromatography trace following incubation of a BRIL fusion protein (∼37 kDa) with BAG2 purified from BL21-Gold indicating two distinct complexes with different retention volumes. The full trace, highlighting the region of interest, is provided as an inset at the top right. (e) SDS–PAGE of size-exclusion chromatography fractions following incubation of a BRIL fusion protein (∼37 kDa) with BAG2 purified from BL21-Gold. Fractions corresponding to complex 1 comprise the expected BRIL fusion protein–BAG2 complex, whilst complex 2 fractions comprise BAG2 in complex with the 15 kDa protein later identified as cytochrome b562.

Originally, we presumed this ∼15 kDa species to arise from proteolytic degradation of BAG2; however, this seemed unlikely given that both species eluted from cation exchange within the same sharp peak (Fig. 1[link]b). Therefore, we proposed the ∼15 kDa band to indicate a co-purifying protein with high affinity for BAG2. This notion was supported via size-exclusion chromatography, which yielded two distinct species following incubation of our purified BAG2 sample with a BRIL fusion protein of ∼37 kDa (Fig. 1[link]d). SDS–PAGE indicated the larger species to comprise the expected BRIL fusion protein–BAG2 complex; however, the ∼15 kDa protein retained in a complex with a substantial proportion of BAG2, eluting as a second, smaller complex (Figs. 1[link]d and 1[link]e).

Both our purified BAG2 sample and SEC fractions comprising the ∼15 kDa protein exhibited a distinct red colour suggestive of an iron-containing molecule, whilst those corresponding to the desired BRIL fusion protein–BAG2 complex were clear. We therefore concluded that BAG2 was likely co-purifying with the native cytochrome b562 (hereafter referred to as cyt b562) present within the E. coli periplasm (Itagaki & Hager, 1966View full citation). Indeed, BRIL is itself a thermostabilized derivative of apocytochrome b562 (Chun et al., 2012View full citation); thus, the ability of the native cytochrome to compete with BRIL for BAG2 binding is unsurprising.

3.2. Determination of the cytochrome b562–BAG2 complex

To confirm our hypothesis that BAG2 was co-purifying with the native cyt b562, we sought to solve the structure of their complex. The cyt b562–BAG2 complex crystallized in space group P65 and diffracted to 2.65 Å resolution, with one copy of each protein in the asymmetric unit (Fig. 2[link]a), resulting in a Matthews coefficient of 3.15 Å3 Da−1 (Matthews, 1968View full citation) and a corresponding solvent content of 61%.

[Figure 2]
Figure 2
Crystal structure of BAG2 in complex with cytochrome b562. (a) Crystal structure of the cytochrome b562–BAG2 complex in cartoon representation. (b) Alignment of our cyt b562–BAG2 structure (blue) with the previously determined BRIL–BAG2 structure (pink; PDB entry 6cbv). (c) Interaction of BAG2 (heavy and light chains in orange and blue, respectively) with cytochrome b562 (depicted as a purple surface). Brackets denote the contributing region of BAG2. (d) Overlaid CDR binding modes of BAG2 in complex with cytochrome b562 and BRIL. Heavy and light chains are coloured orange and blue, respectively, for the cytochrome b562-bound structure and gold and purple, respectively, for the BRIL-bound structure (PDB entry 6cbv). (e) Refined electron density for the BAG2 CDR regions interacting with cytochrome b562. The 2mFoDFc map (grey mesh) is contoured at 1σ and BAG2 is displayed in ball-and-stick representation, coloured by B factor. (f) Refined electron density for the cytochrome b562 heme group. The 2mFoDFc map (grey mesh) is contoured at 1σ and the heme group is displayed in ball-and-stick representation.

As expected, our cyt b562–BAG2 complex exhibited an almost identical architecture to that of the previously educated BRIL–BAG2 complex (PDB entry 6cbv), with alignment yielding an r.m.s.d. of 0.539 Å across 529 pruned atom pairs and 0.686 Å across all 539 pairs (Fig. 2[link]b). Furthermore, the BAG2 complementarity-determining regions (CDRs) exhibit the same binding mode in both structures, in which both CDR-H2 and CDR-H3 supplement extensive interactions made by the LC CDRs (Figs. 2[link]c and 2[link]d). The average B factors for our cyt b562–BAG2 complex are relatively high (109 Å2), likely arising due to the high solvent content of the crystal; nevertheless, the electron density for the BAG2 CDRs was well defined, allowing accurate modelling of their interaction with cyt b562 (Fig. 2[link]e). Furthermore, unambiguous density was observed for the heme molecule within the cytochrome (Fig. 2[link]f). Our cyt b562–BAG2 crystal structure demonstrates the ability of BAG2 to form a stable complex with the native cytochrome b562 present within canonical E. coli expression strains.

3.3. Generation of a ΔcybC strain for bacterial BAG2 expression

Given the propensity of BAG2 to bind native cytochrome b562, we investigated possible methods to prevent their co-purification entirely. We noted the superfluous nature of cyt b562 given that disruption of the cybC gene prevents its expression in E. coli K strains (Trower, 1993View full citation). Thus, we hypothesized that deletion of the cybC gene from a typical B-lineage E. coli expression strain would directly enable contaminant-free BAG2 expression and purification.

Utilizing Datsenko and Wanner gene inactivation, we replaced the cybC ORF within the E. coli T7 Express strain with a kanamycin cassette and subsequently P1-transduced the mutant allele into a fresh background (Figs. 3[link]a and 3[link]b). Expression utilizing this engineered strain, followed by the same Protein L and cation-exchange purification, yielded a pure BAG2 sample (Figs. 3[link]c, 3[link]d and 3[link]e) that formed only the desired BRIL fusion protein–BAG2 complex (Figs. 3[link]f and 3[link]g). Indeed, in our hands, BAG2 was sufficiently clean following Protein L purification that the elution fractions may be dialysed directly, avoiding the necessity for a subsequent cation-exchange step (Fig. 3[link]c).

[Figure 3]
Figure 3
Generation of a ΔcybC strain for bacterial BAG2 expression. (a) Gel electrophoresis of colony PCR amplifying the WT T7 Express cybC locus using flanking primers. (b) Gel electrophoresis of colony PCR amplifying the T7 Express ΔcybC::aph locus using flanking primers. (c) SDS–PAGE of Protein L elution fractions following BAG2 overexpression in T7 Express ΔcybC indicating no co-purifying proteins. (d) Cation-exchange trace of pooled Protein L elution fractions following BAG2 overexpression in T7 Express ΔcybC. (e) SDS–PAGE of cation-exchange fractions following BAG2 overexpression in T7 Express ΔcybC. (f) Size-exclusion chromatography trace following incubation of a BRIL fusion protein (∼37 kDa) with BAG2 purified from T7 Express ΔcybC indicating complete formation of the desired complex. (g) SDS–PAGE of the size-exclusion chromatography fractions following incubation of a BRIL fusion protein (∼37 kDa) with BAG2 purified from T7 Express ΔcybC.

4. Discussion and conclusions

The use of monoclonal fragments antigen binding (Fabs) is a prevalent methodology facilitating protein structure determination via both crystallography and cryo-EM. The development of a synthetic Fab against the BRIL domain improved accessibility to this approach, providing a general fiducial applicable to any protein of interest via the simple curation of a BRIL fusion protein (Mukherjee et al., 2020View full citation).

We observed BAG2 to co-purify with the native E. coli cytochrome b562, which hindered the assembly of our desired BRIL fusion protein–BAG2 complex (Figs. 1[link]d and 1[link]e). Consequently, we constructed a T7 Express ΔcybC strain, allowing the production of a pure BAG2 sample from a simple Protein L purification (Fig. 3[link]c).

Nonetheless, we emphasize that several publications have previously expressed and purified BAG2 from unmodified E. coli strains without issue (Mukherjee et al., 2020View full citation; Sverak et al., 2024View full citation; Tsutsumi et al., 2020View full citation); thus, the maintained inter­action between BAG2 and cyt b562 appears to result from minor differences during purification. Indeed, Mukherjee et al. (2020View full citation) recommend incubation of the bacterial lysate at 60–63°C for 30 min to denature bacterial proteins and Fab degradation products. In contrast, our incubation at 58°C for the same duration appears to be insufficient to completely dissociate the unwanted complex, implying the incubation temperature to be a critical factor in ensuring efficacious purification of BAG2 from canonical E. coli expression strains.

Nevertheless, our T7 Express ΔcybC strain offers an alternative bacterial system for the expression of BAG2, which completely prevents its association with cytochrome b562 whilst also providing an efficient and affordable substitute to the insect and mammalian systems also utilized (Dang et al., 2022View full citation; Kugawa et al., 2025View full citation). Whilst we demonstrated the efficacy of our ΔcybC strain for BAG2, we speculate that it may also provide a useful resource for the expression of any previously developed synthetic anti-BRIL Fab (BAG5, BAK5 and BAK7; Mukherjee et al., 2020View full citation).

Acknowledgements

We thank Anthony Kossiakoff and Somnath Mukherjee, University of Chicago, for the kind gift of the BAG2 expression construct and protocols. We also thank Ed Lowe and the beamline scientists at Diamond Light Source for their help with crystallographic data collection and access to beamline I04 under proposal mx38144.

Conflict of interest

The authors declare no conflicts of interest.

Data availability

The structure factors and model of the native cytochrome b562–BAG2 complex have been deposited in the Protein Data Bank (PDB entry 9tmp).

Funding information

We would like to thank the following funding sources: MR/W016672/1 (MRC Career Development Award to GLI) and 101162143 – LipidBarriers (ERC Starting Grant Awarded to GLI).

References

Return to citationChua, E. Y. D., Mendez, J. H., Rapp, M., Ilca, S. L., Tan, Y. Z., Maruthi, K., Kuang, H., Zimanyi, C. M., Cheng, A., Eng, E. T., Noble, A. J., Potter, C. S. & Carragher, B. (2022). Annu. Rev. Biochem. 91, 1–32.  Web of Science CrossRef CAS PubMed Google Scholar
Return to citationChun, E., Thompson, A. A., Liu, W., Roth, C. B., Griffith, M. T., Katritch, V., Kunken, J., Xu, F., Cherezov, V., Hanson, M. A. & Stevens, R. C. (2012). Structure, 20, 967–976.  Web of Science CrossRef CAS PubMed Google Scholar
Return to citationDang, Y., Zhou, D., Du, X., Zhao, H., Lee, C.-H., Yang, J., Wang, Y., Qin, C., Guo, Z. & Zhang, Z. (2022). Cell. Discov. 8, 141.  CrossRef PubMed Google Scholar
Return to citationDatsenko, K. A. & Wanner, B. L. (2000). Proc. Natl Acad. Sci. USA, 97, 6640–6645.  Web of Science CrossRef PubMed CAS Google Scholar
Return to citationDe Zorzi, R., Mi, W., Liao, M. & Walz, T. (2016). Microscopy (Tokyo), 65, 81–96.  CrossRef Google Scholar
Return to citationEmsley, P. & Cowtan, K. (2004). Acta Cryst. D60, 2126–2132.  Web of Science CrossRef CAS IUCr Journals Google Scholar
Return to citationGorrec, F. (2009). J. Appl. Cryst. 42, 1035–1042.  Web of Science CrossRef CAS IUCr Journals Google Scholar
Return to citationItagaki, E. & Hager, L. P. (1966). J. Biol. Chem. 241, 3687–3695.  CrossRef PubMed Google Scholar
Return to citationKermani, A. A. (2021). FEBS J. 288, 5788–5804.  CrossRef PubMed Google Scholar
Return to citationKim, J., Tan, Y. Z., Wicht, K. J., Erramilli, S. K., Dhingra, S. K., Okombo, J., Vendome, J., Hagenah, L. M., Giacometti, S. I., Warren, A. L., Nosol, K., Roepe, P. D., Potter, C. S., Carragher, B., Kossiakoff, A. A., Quick, M., Fidock, D. A. & Mancia, F. (2019). Nature, 576, 315–320.  Web of Science CrossRef CAS PubMed Google Scholar
Return to citationKugawa, M., Kawakami, K., Kise, R., Suomivuori, C.-M., Tsujimura, M., Kobayashi, K., Kojima, A., Inoue, W. J., Fukuda, M., Matsui, T. E., Fukunaga, A., Koyanagi, J., Kim, S., Ikeda, H., Yamashita, K., Saito, K., Ishikita, H., Dror, R. O., Inoue, A. & Kato, H. E. (2025). Nat. Commun. 16, 2809.  CrossRef PubMed Google Scholar
Return to citationLiebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung, L.-W., Jain, S., McCoy, A. J., Moriarty, N. W., Oeffner, R. D., Poon, B. K., Prisant, M. G., Read, R. J., Richardson, J. S., Richardson, D. C., Sammito, M. D., Sobolev, O. V., Stockwell, D. H., Terwilliger, T. C., Urzhumtsev, A. G., Videau, L. L., Williams, C. J. & Adams, P. D. (2019). Acta Cryst. D75, 861–877.  Web of Science CrossRef IUCr Journals Google Scholar
Return to citationLuo, P., Xin, W., Guo, S., Li, X., Zhang, Q., Xu, Y., He, X., Wang, Y., Fan, W., Yuan, Q., Wu, K., Hu, W., Zhuang, Y., Xu, H. E. & Xie, X. (2025). Cell. Discov. 11, 7.  CrossRef PubMed Google Scholar
Return to citationMatthews, B. W. (1968). J. Mol. Biol. 33, 491–497.  CrossRef CAS PubMed Web of Science Google Scholar
Return to citationMcCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674.  Web of Science CrossRef CAS IUCr Journals Google Scholar
Return to citationMukherjee, S., Erramilli, S. K., Ammirati, M., Alvarez, F. J. D., Fennell, K. F., Purdy, M. D., Skrobek, B. M., Radziwon, K., Coukos, J., Kang, Y., Dutka, P., Gao, X., Qiu, X., Yeager, M., Xu, H. E., Han, S. & Kossiakoff, A. A. (2020). Nat. Commun. 11, 1598.   Google Scholar
Return to citationMukherjee, S., Ura, M., Hoey, R. J. & Kossiakoff, A. A. (2015). J. Mol. Biol. 427, 2707–2725.  Web of Science CrossRef PubMed Google Scholar
Return to citationPan, Y., Ren, Z., Gao, S., Shen, J., Wang, L., Xu, Z., Yu, Y., Bachina, P., Zhang, H., Fan, X., Laganowsky, A., Yan, N. & Zhou, M. (2020). Nat. Commun. 11, 5686.  Web of Science CrossRef PubMed Google Scholar
Return to citationShionoya, K., Park, J.-H., Ekimoto, T., Takeuchi, J. S., Mifune, J., Morita, T., Ishimoto, N., Umezawa, H., Yamamoto, K., Kobayashi, C., Kusunoki, A., Nomura, N., Iwata, S., Muramatsu, M., Tame, J. R. H., Ikeguchi, M., Park, S.-Y. & Watashi, K. (2024). Nat. Commun. 15, 9241.  CrossRef PubMed Google Scholar
Return to citationSverak, H. E., Yaeger, L. N., Worrall, L. J., Vacariu, C. M., Glenwright, A. J., Vuckovic, M., Al Azawi, Z.-D., Lamers, R. P., Marko, V. A., Skorupski, C., Soni, A. S., Tanner, M. E., Burrows, L. L. & Strynadka, N. C. J. (2024). Nat. Commun. 15, 9936.  CrossRef PubMed Google Scholar
Return to citationThomason, L. C., Costantino, N. & Court, D. L. (2007). Curr. Protoc. Mol. Biol. 79, 1.17.1–1.17.8.  CrossRef Google Scholar
Return to citationTrower, M. K. (1993). Biochim. Biophys. Acta, 1143, 109–111.  CrossRef PubMed Google Scholar
Return to citationTsutsumi, N., Mukherjee, S., Waghray, D., Janda, C. Y., Jude, K. M., Miao, Y., Burg, J. S., Aduri, N. G., Kossiakoff, A. A., Gati, C. & Garcia, K. C. (2020). eLife. 9, e58464.  CrossRef PubMed Google Scholar
Return to citationWalsh, R. M., Roh, S.-H., Gharpure, A., Morales-Perez, C. L., Teng, J. & Hibbs, R. E. (2018). Nature, 557, 261–265.  Web of Science CrossRef CAS PubMed Google Scholar
Return to citationWinter, G. (2010). J. Appl. Cryst. 43, 186–190.  Web of Science CrossRef CAS IUCr Journals Google Scholar
Return to citationWinter, G., Waterman, D. G., Parkhurst, J. M., Brewster, A. S., Gildea, R. J., Gerstel, M., Fuentes-Montero, L., Vollmar, M., Michels-Clark, T., Young, I. D., Sauter, N. K. & Evans, G. (2018). Acta Cryst. D74, 85–97.  Web of Science CrossRef IUCr Journals Google Scholar
Return to citationWu, S., Avila-Sakar, A., Kim, J., Booth, D. S., Greenberg, C. H., Rossi, A., Liao, M., Li, X., Alian, A., Griner, S. L., Juge, N., Yu, Y., Mergel, C. M., Chaparro-Riggers, J., Strop, P., Tampé, R., Edwards, R. H., Stroud, R. M., Craik, C. S. & Cheng, Y. (2012). Structure, 20, 582–592.  Web of Science CrossRef CAS PubMed Google Scholar
Return to citationZhang, L., Mobbs, J. I., Bennetts, F. M., Venugopal, H., Nguyen, A. T. N., Christopoulos, A., van der Es, D., Heitman, L. H., May, L. T., Glukhova, A. & Thal, D. M. (2025). Nat. Commun. 16, 7674.  CrossRef PubMed Google Scholar

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.

Journal logoSTRUCTURAL BIOLOGY
COMMUNICATIONS
ISSN: 2053-230X
Follow Acta Cryst. F
Sign up for e-alerts
Follow Acta Cryst. on Twitter
Follow us on facebook
Sign up for RSS feeds